- |||||||||| Macrilen (macimorelin) / AEterna Zentaris
Review, Journal: Once upon a time: the glucagon stimulation test in diagnosing adult GH deficiency. (Pubmed Central) - Mar 10, 2024 Our results suggest D-Cys6-LHRH vedotin can potentially be used as a treatment for ovarian cancer. This document provides an update on the utility of GST, summarizes how to perform the test, shows which cut-points should be used in interpreting the results, and discusses its drawbacks and caveats referring to the most recent studies.
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula. (Pubmed Central) - Feb 5, 2024 PLR and NLR could be used to predict the efficacy of neoadjuvant therapy with the taxane, anthracycline, and lobaplatin regimen for patients with TNBC, as patients who had lower PLR and NLR values had a higher tpCR rate and a better long-term prognosis. After radiation therapy, the patient continued to be treated with anlotinib and immunotherapy with camrelizumab, and the patient's lesion improved.
- |||||||||| lobaplatin (D19466) / AEterna Zentaris, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Cyramza (ramucirumab) / Eli Lilly
Enrollment open, Enrollment change, Metastases: Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer (clinicaltrials.gov) - Jan 23, 2024 P4, N=140, Recruiting, Treatment of cells with AMD3100, a CXCR4 antagonist, and G-CSF blocked the CXCL12/CXCR4 axis, inducing biological changes in the leukaemia cells and altering IL-8 and IL-6 levels...ELISA results confirmed that MG-132 (10 Not yet recruiting --> Recruiting | N=48 --> 140
- |||||||||| lobaplatin (D19466) / AEterna Zentaris
Journal, Metastases: Mechanism of gemcitabine combined with lobaplatin in interventional treatment of locally advanced cervical cancer. (Pubmed Central) - Jan 9, 2024 There was no significant difference in the serum VEGF and MMP-9 levels between the two groups before treatment (P?>?0.05); after treatment, the serum VEGF and MMP-9 levels in the experimental group were significantly lower than those in the control group, P?<?0.05. Therefore, gemcitabine combined with lobaplatin interventional therapy can improve the cure rate of LACC by reducing VEGF and MMP-9 levels in the serum of patients.
- |||||||||| perifosine (D21266) / AEterna Zentaris
Journal: Mitochondrial Functionality Is Regulated by Alkylphospholipids in Human Colon Cancer Cells. (Pubmed Central) - Dec 22, 2023 These alterations led to higher mitochondrial membrane potential, which was potentiated by decreased uncoupling protein 2 (UCP2) levels and increased reactive oxygen species (ROS) production. Consequently, perifosine induced an imbalance in mitochondrial function, resulting in higher ROS production that ultimately impacted cellular viability.
- |||||||||| lobaplatin (D19466) / AEterna Zentaris, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Cyramza (ramucirumab) / Eli Lilly
New P4 trial, Metastases: Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer (clinicaltrials.gov) - Dec 13, 2023 P4, N=48, Not yet recruiting,
- |||||||||| Macrilen (macimorelin) / AEterna Zentaris
Review, Journal: New insights on diagnosis and treatment of AVP deficiency. (Pubmed Central) - Dec 12, 2023 In general, treatment of AVP-D focuses on desmopressin substitution, with oral formulations currently showing the best tolerance and safety profile. However, in addition to desmopressin substitution, recent data also showed that psychopathological factors play an important role in managing AVP-D patients.
- |||||||||| perifosine (D21266) / AEterna Zentaris
Journal: Germline PTEN genotype-dependent phenotypic divergence during the early neural developmental process of forebrain organoids. (Pubmed Central) - Nov 30, 2023 Perifosine, an AKT inhibitor, reduced over-activated AKT and partially corrected the abnormalities in cellular organization observed in PTEN organoids...These findings demonstrate that different PTEN missense mutations can have a profound impact on neurodevelopment at diverse stages which in turn may predispose PHTS individuals to ASD. Further study will shed light on ways to mitigate pathological impact of PTEN mutants on neurodevelopment by stage-specific manipulation of downstream PTEN signaling components.
- |||||||||| lobaplatin (D19466) / AEterna Zentaris
Review, Journal, BRCA Biomarker: Platinum-based chemotherapy for early triple-negative breast cancer. (Pubmed Central) - Sep 12, 2023 These findings support the use of platinum-based chemotherapy for people with early TNBC. The optimal dose and regimen are not defined by this analysis, but there is a suggestion that similar relative benefits result from the addition of carboplatin to either anthracycline-free regimens or those containing anthracycline agents.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, perifosine (D21266) / AEterna Zentaris, ABT-737 / AbbVie
Review, Journal: Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma. (Pubmed Central) - Aug 7, 2023 These compounds are implicated in the therapeutic management of NSCLC. This review further offers deeper mechanistic insights into different signaling pathways that could be targeted for NSCLC therapy by phytochemicals and small-molecule inhibitors.
- |||||||||| perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Trial completion: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas (clinicaltrials.gov) - May 25, 2023 P1, N=10, Completed, These findings highlight the importance of AKT in contributing to immune evasion mechanisms in acute myeloid leukemia and suggests the potential of AKT inhibition as an adjunct to immunotherapy. Active, not recruiting --> Completed
- |||||||||| Baizean (tislelizumab) / BeiGene, Novartis, TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
A retrospective analysis of tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy plus nimotuzumab in patients with high-risk nasopharyngeal carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5686; The patients had received neoadjuvant chemotherapy (gemcitabine,1000 mg/m2, days 1 and 8, cisplatin,80 mg/m2, day 1), and tislelizumab (200mg) on day 1 every 3 weeks for 4 cycles followed by chemoradiotherapy including intensity modulated radiotherapy (IMRT), lobaplatin and nimotuzumab. Neoadjuvant therapy with tislelizumab and GP regimen followed by concurrent chemoradiotherapy plus nimotuzumab seems to have promising efficacy, lower toxic effects and better treatment compliance, which is a new treatment strategy for high-risk NPC.
- |||||||||| lobaplatin (D19466) / AEterna Zentaris, AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
Journal, PD(L)-1 Biomarker, Metastases: Efficacy and safety of Camrelizumab combined with Abraxane + lobaplatin regimen for advanced gastric cancer. (Pubmed Central) - Mar 15, 2023 The knockdown of LBP facilitated adipose browning, glucose uptake, and oxygen consumption in MEFs via the activation of PI3K/Akt/mTOR pathway and the inhibition of autophagy. The combination of Camrelizumab and Abraxane + lobaplatin is an effective treatment for advanced gastric cancer and can increase the patient's survival rate.
- |||||||||| MK-2206 / Merck (MSD), perifosine (D21266) / AEterna Zentaris, AT13148 / Otsuka
Targeted investigational oncology agents (IOA) in the NCI60: a phenotypic systems-based resource (Section 13; Poster Board #27) - Mar 14, 2023 - Abstract #AACR2023AACR_7230; The AKT cluster includes both allosteric (MK-2206) and competitive inhibitors highlighting the NCI60 is a functional cell assay...The mTOR inhibitors (12/20) form a connected cluster at 0.7 COMPARE correlation, with half of the non-connected mTOR singletons representative of the rapamycin class of inhibitors...NCI60 compound suppliers can incorporate their test compound(s) data to use the interactive visualization tools with AOD and IOA agents. This project was funded in part with federal funds from the NCI, NIH, under Contract # 75N91019D00024/75N91020F00003.
- |||||||||| Macrilen (macimorelin) / AEterna Zentaris, Novo Nordisk
Journal: Macimorelin Acetate for the Diagnosis of Childhood-onset Growth Hormone Deficiency. (Pubmed Central) - Jan 26, 2023 Despite the widespread use of these tests, various criticisms have been levelled against them, such as the labour-intensive nature of the tests, their potential for serious adverse effects and their questionable reproducibility. Macimorelin acetate, a ghrelin mimetic approved for the diagnosis of adult growth hormone deficiency, could serve an unmet need in the diagnosis of childhood-onset growth hormone deficiency based on its good tolerability and benign side effect profile.
- |||||||||| perifosine (D21266) / AEterna Zentaris, ABT-737 / AbbVie
Journal: Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells. (Pubmed Central) - Dec 17, 2022 While the cytotoxicity of single agents was influenced by the tumour-specific microenvironment, perifosine and ABT-737 in combination synergistically induced apoptosis in cells cultured in both 2D and 3D independently on pH and oxygen level. Thus, the combined therapy of perifosine and ABT-737 could be considered as a potential treatment strategy for colon cancer.
|